dm+d

Unassigned

New Medicines

Systemic lupus erythematosus (SLE)

Information

New molecular entity
Biogen
Biogen

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Humanised, monovalent pegylated Fab antibody fragment against the CD40 ligand, CD40L
Lupus affected nearly 1 in 1,000 of the population in 2012 in the UK. The age-standardised incidence in the UK is 8.3 per 100,000/year for females and 1.4 per 100,000/year for males in the UK [1].
Systemic lupus erythematosus (SLE)
Intravenous infusion